ObesityWeek 2026 late-breakers start to surface

ObesityWeek 2026 runs November 14 to 17 in Washington, DC, and it is shaping up as the year's biggest showcase for experimental obesity treatments outside the GLP-1 class already sold as Ozempic, Wegovy, Mounjaro and Zepbound. Several companies have confirmed late-breaking data slots, and some have already released results ahead of the meeting.

Corbus Pharmaceuticals announced topline results from its CANYON-1 study of CRB-913, a once-daily oral pill that works differently from GLP-1 drugs by blocking a receptor called CB1 outside the brain rather than mimicking gut hormones ^[1]. In the 254-person, 16-week study, people taking the 60 mg dose lost a placebo-adjusted 5.0% of body weight at 12 weeks, compared with 3.3% at 40 mg and 2.8% at 20 mg, with all differences statistically significant (p<0.0001) ^[1]. Weight loss had not leveled off by week 12, and the largest individual loss recorded was 13.4% ^[1].

Corbus reported fewer stomach-related side effects than oral GLP-1 drugs in a cross-trial comparison, not a head-to-head trial. Vomiting occurred in 1.6% to 8.2% of CRB-913 patients versus 14% to 31% with oral semaglutide or orforglipron in separate published studies, and nausea was 15.4% to 26.2% versus 41% to 48% ^[1]. Among 188 people who took CRB-913, one had a moderate depressive symptom and there were no reports of suicidal thoughts, according to the company ^[1]. Corbus plans to discuss the data with the FDA and start a Phase 2 monotherapy trial in the first half of 2027, and is also looking at combining CRB-913 with GLP-1 therapy ^[1].

Biomed Industries has a Phase 2 late-breaking abstract confirmed for ObesityWeek 2026 titled "Phase 2 Study of NA-931, a Quadruple Receptor Agonist, Demonstrates Significant Weight Loss With Preservation of Lean Mass," though the full data have not yet been made public ^[2]. NA-931 targets four pathways at once — IGF-1, GLP-1, GIP and glucagon. In an earlier study presented at ObesityWeek 2025, weight loss over 13 weeks ranged from 5.5% at 60 mg to 13.8% at 150 mg, compared with 1.9% for placebo, with the two higher doses reaching statistical significance ^[2]. Biomed is also planning Phase 3 trials of NA-931 alone and combined with oral semaglutide, expecting to enroll about 466 adults with a 52-week endpoint, plus two additional 68-week trials pairing NA-931 with semaglutide or tirzepatide ^[2].

A third program, from MannKind and Rose Pharma, has an accepted abstract on patient preference for a rapid-acting, short-duration GLP-1 drug. Specific data or study details for that abstract are not yet available in the materials reviewed for this story.

Why it matters for patients

Most people currently using GLP-1 drugs take an injection or a pill that acts on gut hormone receptors, and side effects like nausea and vomiting are common reasons people stop treatment. Corbus cited an investigator's estimate that more than 60% of patients discontinue GLP-1 treatment within the first year ^[1]. A pill with a different mechanism and reportedly milder GI side effects, if it holds up in larger and longer trials, could eventually offer an alternative for people who cannot tolerate current options. Similarly, a four-target drug like NA-931 that claims to preserve lean muscle mass, if confirmed, could matter for patients concerned about losing muscle along with fat. None of these drugs are approved, and the numbers so far come from early- and mid-stage trials with only 12 to 16 weeks of data, far short of the year or more used to evaluate approved GLP-1 drugs.

What happens next

Full data on CRB-913, NA-931 and other late-breaking programs are expected to be presented at ObesityWeek 2026 in Washington, DC, from November 14 to 17. Corbus expects to start a Phase 2 monotherapy trial for CRB-913 in the first half of 2027 ^[1]. Biomed Industries' Phase 3 program for NA-931 is planned pending regulatory and operational readiness, with no confirmed start date yet ^[2].